Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** Not yet assigned (Continuation of 09/857,332) INFORMATION DISCLOSURE Filing Date March 23, 2004 STATEMENT BY APPLICANT **First Named Inventor** N. Phillips (use as many sheets as necessary **Group Art Unit** Not yet assigned **Examiner Name** Not yet assigned Sheet of 2 Attorney Docket Number 02811-0152 (42368-298888)

U.S. PATENT DOCUMENTS						
Examiner Ci	ite o.' Number	O N	Patent Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X=N 1	6,326,357	1		Phillips et al.	12-04-2001	
Sur 3	6,329,347	2		Phillips et al.	12-11-2001	
		-				
		-				
		1		· · · · · · · · · · · · · · · · · · ·		
		-				
				<u> </u>		
						· · · · · · · · · · · · · · · · · · ·

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	$\top$
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	τ°
ark	3	wo	99 07383		Bioniche Inc.	02-18-1999		
0							· · ·	$\top$
								$\Box$

11-12-05 Examiner Date Signature Considered

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard SŢ.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute f	or Form 1449/A/PTO			Application Number	Not yet assigned (Continuation of	
1		riAi	N DISCLOSURE		09/857,332)	
ł				Filing Date	March 23, 2004	
	STATEME	NT I	BY APPLICANT	First Named Inventor	N. Phillips	
	(use as i	many si	neets as necessary	Group Art Unit	Not yet assigned	
				Examiner Name	Not yet assigned	
Sheet	2	of	2	Attorney Docket Number	02811-0152 (42368-298888)	

Examiner tritiats  Cite No.  Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  Filion, M.C., et al, Mycobacterial Dna Induces Apoptosis In Myeloid Leukemia Cell Lines", Thirty-Ninth Annual Meeting Of The American Society Of Hematology, San Diego, California, Vol. 90 (10 Supp., 1 part 2) (December 5-9, 1997)	T <sup>2</sup>
Lines", Thirty-Ninth Annual Meeting Of The American Society Of Hematology, San	
Diego, California, Vol. 90 (10 Supp., 1 part 2) (December 5-9, 1997)	
Filion, M.C., et al., "Mycobacterial Cell Wall-DNA Complex Induces Apoptosis in Cancer Cells", Database Biosis Online, Biosciences Information Service, Philadelphia, PA, XP002133100, J. of Pharmacy and Pharmacology, 135th Meeting of the British Pharmaceutical Conference Eastbourne, England UK, Vol. 50, p. 39 (September 8-11, 1998)	
<sup>6</sup> Filion, M.C., et al., "Mycobacterial Phlei Cell Wall Complex, a New Anti-Tumoral	
Agent, Induces IL-12 Synthesis By Monocyte-Macrophages Via Associated DNA",	
Third-Ninth Annual Meeting of the American Society of Hematology, San Diego, California, <i>Blood</i> , Vol. 90 (10 Supp. 1 part 2) (December 5-9 1997)	
Filion, et al., "Toxicity and Immunomodulatory Activity of Liposomal Vectors	
Formulated with Cationic Lipids Toward Immune Effector Cells", Biochim. Biophys.	
Acta, Vol. 1329, pp. 345-356 (1997)	
Phillips, et al, "Influence of Phosphlipid Compositions on Antibody Responses to	
Liposome Encapsulated Protein and Peptide Antigens", Vaccine, Vol. 14, No. 9, pp. 898	3-
904 (1996)	
Yamamoto, S., et al., "In vitro Augmentation of Natural Killer Cell Activity and	
Production of Interferon- $\alpha/\beta$ and $-y$ with Deoxyribonucleic Acid Fraction From	
Mycobacterium bovis BCG", Jpn. J. Cancer Res., Vol. 79, pp 866-873	1 1